卒中作为全球重大疾病负担，其高死亡率、高致残率对家庭和社会构成严峻威胁。在我国，急性缺血性卒中（AIS）约占新发卒中病例的70%，是导致患者神经功能缺损和长期残疾的主要原因。AIS的治疗关键在于尽早实现血管再通，挽救缺血半暗带。静脉溶栓因可恢复脑血流，改善神经功能，已成为再灌注治疗的基石策略。近年来，静脉溶栓药物研发不断取得突破性进展，为更多AIS患者带来了获益契机。重组人尿激酶原（rhPro-...
Source Link卒中作为全球重大疾病负担，其高死亡率、高致残率对家庭和社会构成严峻威胁。在我国，急性缺血性卒中（AIS）约占新发卒中病例的70%，是导致患者神经功能缺损和长期残疾的主要原因。AIS的治疗关键在于尽早实现血管再通，挽救缺血半暗带。静脉溶栓因可恢复脑血流，改善神经功能，已成为再灌注治疗的基石策略。近年来，静脉溶栓药物研发不断取得突破性进展，为更多AIS患者带来了获益契机。重组人尿激酶原（rhPro-...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.